← Volver a resultados
Ficha bibliográfica · Consulta y acceso
Artículo

The Clinical Outcomes of Tocilizumab Usage in Cryptogenic Febrile Infection-Related Epilepsy Syndrome at Both Acute and Chronic Phase: A Retrospective Study

Deng X et al · Dove Medical Press · 2026

Acceso abierto al texto completo
Lectura rápida. Revisá los datos básicos del recurso y luego accedé al contenido desde el botón principal. En esta ficha solo se muestra la información necesaria para identificar la obra, citarla y abrirla.

Acceso al recurso

Entrá al contenido desde la opción principal o elegí otra fuente disponible.

Acceso principal

Acceso abierto al texto completo

Texto completo identificado como acceso abierto.
Abrir texto

Resumen

Descripción general del contenido del recurso.

Xiaolu Deng,1,2 Shimeng Chen,1,2 Fei Yin,1,2 Fang He,1,2 Ciliu Zhang,1,2 Lifen Yang,1,2 Leilei Mao,1,2 Li Yang,1,2 Yang Han,1,2 Jing Peng1,2 1Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, 410000, People’s Republic of China; 2Clinical Research Center for Children Neurodevelopmental Disabilities of Hunan Province, Xiangya Hospital, Central South University, Changsha, 410000, People’s Republic of ChinaCorrespondence: Jing Peng, Email pengjing627@126.comPurpose: To provide more observational evidence for potential efficacy of tocilizumab (TCZ) in children with cryptogenic febrile infection-related epilepsy syndrome (FIRES) administered during acute and chronic phase.Methods: Data of 22 children with FIRES who received TCZ were collected retrospectively. Patients were categorized into two groups: acute group (TCZ used within 4 weeks post-onset; n = 12) and chronic group (TCZ used beyond 4 weeks post-onset; n = 10).Results: In both groups, patients experienced > 50% reduction in seizure frequency, electroencephalogram (EEG) improvements, alleviation on cranial magnetic resonance imaging (MRI), and significantly decreased mRS scores (P < 0.05). In acute group, 6 patients became seizure-free by the last follow-up, and 7 patients reduced their number of antiseizure medications (ASMs). TCZ administration in acute phase shortened status epilepticus (SE) duration. At last follow-up, the acute group exhibited higher rates of seizure freedom and > 50% seizure reduction (P < 0.05), lower incidences of motor and speech deficits (P < 0.05), and a greater likelihood of returning to school (P < 0.05).Conclusion: TCZ treatment was associated with reduced seizure frequency, improved EEG and MRI findings, decreased reliance on antiseizure medications, and functional improvement as measured by mRS. Initiation of treatment during the acute phase may be associated with a shortened duration of status epilepticus and, compared to chronic-phase intervention, appears to correlate with more favorable long-term outcomes.Keywords: FIRES, TCZ, outcomes, chronic phase, acute phase

Cómo citar

Elegí el formato que necesitás y copiá la referencia al portapapeles.

APA 7

al, D. X. E. (2026). The Clinical Outcomes of Tocilizumab Usage in Cryptogenic Febrile Infection-Related Epilepsy Syndrome at Both Acute and Chronic Phase: A Retrospective Study. https://www.dovepress.com/the-clinical-outcomes-of-tocilizumab-usage-in-cryptogenic-febrile-infe-peer-reviewed-fulltext-article-JIR

MLA

al, Deng X et. "The Clinical Outcomes of Tocilizumab Usage in Cryptogenic Febrile Infection-Related Epilepsy Syndrome at Both Acute and Chronic Phase: A Retrospective Study." 2026. https://www.dovepress.com/the-clinical-outcomes-of-tocilizumab-usage-in-cryptogenic-febrile-infe-peer-reviewed-fulltext-article-JIR.

Chicago

al, Deng X et. 2026. "The Clinical Outcomes of Tocilizumab Usage in Cryptogenic Febrile Infection-Related Epilepsy Syndrome at Both Acute and Chronic Phase: A Retrospective Study.". https://www.dovepress.com/the-clinical-outcomes-of-tocilizumab-usage-in-cryptogenic-febrile-infe-peer-reviewed-fulltext-article-JIR.

Harvard

al, D. X. E. 2026, The Clinical Outcomes of Tocilizumab Usage in Cryptogenic Febrile Infection-Related Epilepsy Syndrome at Both Acute and Chronic Phase: A Retrospective Study, Dove Medical Press, available at: https://www.dovepress.com/the-clinical-outcomes-of-tocilizumab-usage-in-cryptogenic-febrile-infe-peer-reviewed-fulltext-article-JIR [Accessed 29 Jun. 2026].

Compartir e imprimir

Guardá la ficha, copiá su enlace permanente o imprimila como PDF.

Exportar referencia

Si usás un gestor bibliográfico, podés exportar el registro en los formatos más comunes.

Detalles del recurso

Información bibliográfica útil para confirmar que se trata del material correcto.

Título
The Clinical Outcomes of Tocilizumab Usage in Cryptogenic Febrile Infection-Related Epilepsy Syndrome at Both Acute and Chronic Phase: A Retrospective Study
Autor / colaboradores
Deng X et al
Editorial
Dove Medical Press
Año de publicación
2026
ISSN
1178-7031
ISSN
1178-7031
Idioma
eng

Materias

Explorá otros recursos relacionados a partir de estas materias.

Copiado